Adcentrx Therapeutics Inc.
United States
9 articles about Adcentrx Therapeutics Inc.
-
Adcentrx Therapeutics to Present Preclinical Data for Nectin-4 ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
4/1/2024
Adcentrx Therapeutics ("Adcentrx") today announced that preclinical data for ADRX-0706 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.
-
Adcentrx Announces Extension of Series A+ Financing to $51 Million
12/6/2023
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.
-
Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
9/27/2023
Adcentrx Therapeutics today announced the first patient dosed in the Phase 1a/b study of ADRX-0706 for the treatment of advanced solid tumors.
-
Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
7/17/2023
Adcentrx Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application of ADRX-0706 for the treatment of select advanced solid tumors.
-
Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures
4/25/2023
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announces the closing of a $38 million Series A+ financing.
-
Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.
-
The three-year agreement leverages AvantGen's yeast display technology for antibody discovery optimization to engineering antibodies into Antibody-Drug Conjugate treatments.
-
Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates
2/14/2022
Adcentrx Therapeutics ("Adcentrx"), and AvantGen, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.
-
Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development
4/28/2021
Adcentrx Therapeutics ("Adcentrx"), a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, announced the closing of $50m Series A financing to power the development of next generation ADC for improving patient treatment options.